Dr. Whitman on the Partnership Between Atlantic Health System, TGen and Origin

Eric Whitman, MD
Published: Friday, Oct 05, 2018



Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses the partnership between Atlantic Health System, Translational Genomics Research Institute (TGen), and Origin Commercial Ventures.

On October 4 2018, Atlantic Health System announced a partnership with the Translational Genomics Research Institute and Origin Commercial Ventures to create a new platform to deliver economically accessible immunotherapies and other prominent cancer therapies to the region.

The goal behind the partnership, says Whitman, is to improve the drug pipeline, so that physicians at Atlantic Health have local access to the best therapies and technologies for patients. Community oncologists are very excited by the partnership, explains Whitman, as it enables their patients to stay within the community. Traditionally, a patient who has expended all of their options is referred to a center that is far away. Now, a patient can be referred to a research center on site, enabling much better in-house communication.
SELECTED
LANGUAGE


Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses the partnership between Atlantic Health System, Translational Genomics Research Institute (TGen), and Origin Commercial Ventures.

On October 4 2018, Atlantic Health System announced a partnership with the Translational Genomics Research Institute and Origin Commercial Ventures to create a new platform to deliver economically accessible immunotherapies and other prominent cancer therapies to the region.

The goal behind the partnership, says Whitman, is to improve the drug pipeline, so that physicians at Atlantic Health have local access to the best therapies and technologies for patients. Community oncologists are very excited by the partnership, explains Whitman, as it enables their patients to stay within the community. Traditionally, a patient who has expended all of their options is referred to a center that is far away. Now, a patient can be referred to a research center on site, enabling much better in-house communication.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20192.0
Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic MalignanciesApr 30, 20191.5
Publication Bottom Border
Border Publication
x